Posted by Michael Wonder on 03 Dec 2025
Anzupgo (delgocitinib cream) now available in Canada for adult patients living with moderate to severe chronic hand eczema
2 December 2025 - Leo Pharma is pleased to announce the availability of Anzupgo (delgocitinib cream) across Canada for adults living with moderate to severe chronic hand eczema.
This treatment option marks a significant advancement in addressing the unmet needs of Canadian patients struggling with the taxing symptoms of chronic hand eczema, for patients for whom topical corticosteroids are inadequate or are not advisable. Anzupgo received Health Canada approval in August 2025.
On 1 December 2025, Canada's Drug Agency issued a recommendation in favour of reimbursing Anzupgo.
